Market Cap 34.78B
Revenue (ttm) 5.68B
Net Income (ttm) 371.23M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE 38.94
Profit Margin 6.53%
Debt to Equity Ratio 0.34
Volume 100
Avg Vol 588
Day's Range N/A - N/A
Shares Out 189.02M
Stochastic %K 91%
Beta 0.47
Analysts Strong Sell
Price Target $70.00

Company Profile

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company's primary products include Cimzia for inflammatory TNF-mediated diseases, as well as ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson's disease and restless legs...

Industry: Biotechnology
Sector: Healthcare
Phone: 32 2 559 99 99
Fax: 32 2 559 99 00
Website: www.ucb.com
Address:
Allée de la Recherche, 60, Brussels, Belgium
Latest News on UCBJF
No data available.